Biogen Inc. (BIIB)

BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with ...

Biogen beat Q2 2025 revenue and EPS estimates, but core MS and SPINRAZA franchises continue to erode, offset only partially by new products. Launches like ZURZUVAE and LEQEMBI show promise, yet their ...

Biogen Inc. (NASDAQ:BIIB ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Alisha A. Alaimo - President & Head of North America Christopher A.

BIIB posts Q2 earnings and sales beat, lifts 2025 outlook on new drug growth and displays resilient MS performance.

Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street es...

Biogen Inc. (BIIB) came out with quarterly earnings of $5.47 per share, beating the Zacks Consensus Estimate of $3.93 per share. This compares to earnings of $5.28 per share a year ago.

Biogen raised its annual profit forecast on Thursday, betting on strong demand for its rare disease drugs such as Skyclarys to offset declining sales of its older multiple sclerosis drugs.

Besides Wall Street's top-and-bottom-line estimates for Biogen (BIIB), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quar...